November 6, 2019

Roche/Genentech Announces Decision to Discontinue Development of RG6206 (RO7239361)

We are disappointed to learn that Roche/Genentech is discontinuing development of their investigational anti-myostatin adnectin RG6206 (RO7239361) for the treatment of Duchenne. According to the company, this decision was based on results from a pre-planned…

Learn More

July 18, 2019

Roche/Genentech Announces Completed Recruitment for SPITFIRE Study

Roche/Genentech has provided an update to the community announcing that enrollment in the SPITFIRE pivotal study has been officially completed globally at 48 sites across the US, Canada, Argentina, Europe, Australia and Japan. Read Roche/Genentech’s letter…

Learn More

May 31, 2019

WATCH: Domagrozumab as a Potential Treatment for Duchenne – Webinar Recording

On May 22, 2019, Pfizer Inc. joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the primary safety and efficacy results from the Phase 2 clinical trial. Additional…

Learn More

February 27, 2019

Roche/Genentech General Program Update Letter to the Duchenne Community

As Roche/Genentech continues to advance its Phase 2/3 clinical development program for RG6206, an adnectin fusion protein designed to inhibit myostatin and stimulate muscle growth in ambulatory people with Duchenne, the company has provided an…

Learn More

October 15, 2018

WATCH: Is Myostatin Still a Potential Therapeutic Target? – Webinar Recording

Myostatin is a negative regulator of muscle growth – a protein that stops muscle building and doesn’t let them get too big, as part of the natural regeneration process. In other words, if we can…

Learn More

September 13, 2018

Genentech/Roche RG6206 Community Letter

  Today, Roche provided the community on their clinical development program of RG6206, an investigational anti-myostatin adnectin that is designed to block the activity of myostatin. Roche also answers questions they have received in light…

Learn More

August 30, 2018

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne

We are deeply disappointed to learn that Pfizer is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne: a Phase 2 safety and efficacy study (B5161002) and an open-label extension study…

Learn More

May 24, 2018

WATCH: Anti-Myostatin Adnectin RG6206 in Duchenne – Webinar Recording with Roche/Genentech

Roche/Genentech recently joined Parent Project Muscular Dystrophy for a webinar to provide an update on their Anti-Myostatin Adnectin (RG6206) development program. The team at Roche and its US affiliate, Genentech, and provided an overview of…

Learn More

May 9, 2018

May 16 Webinar: Roche/Genentech Anti-Myostatin Adnectin RG6206 in Duchenne

Roche/Genentech will join Parent Project Muscular Dystrophy for a webinar on Wednesday, May 16 at 1:00 PM EDT to provide an update on their Anti-Myostatin Adnectin (RG6206) development program. You will learn more about the team at…

Learn More